Rare Peritoneal Dedifferentiated Liposarcoma Treatment: Breakthrough Case Study by Dr. Manish Singhal

Dedifferentiated Liposarcoma Treatment

In situations where treatments for an aggressive abdominal cancer refuse to respond to standard medical treatments, oncologists have to innovate and design highly customized therapies. Dedifferentiated liposarcoma (DDLPS) is a high-grade, fast-growing soft tissue cancer known for its aggressive biological behavior and its stubborn resistance to standard chemotherapy. While it usually grows deep inside the back of the abdomen or the limbs, finding it primarily on the delicate lining of the abdominal cavity (the peritoneum) is incredibly rare. This unusual presentation creates a massive challenge for doctors trying to get an accurate diagnosis.

Yashoda Medicity, Indirapuram, has revealed a highly successful dedifferentiated liposarcoma treatment with Immunotherapy. Full credit for this medical breakthrough goes to Dr. Manish Singhal. The leading medical oncologist in the Delhi NCR region and the Vice Chairman and Head of Medical Oncology at Yashoda Medicity, as a highly decorated specialist and the very first Indian to top the prestigious global ESMO (European Certified Medical Oncologist) examination, Dr. Manish Singhal successfully designed a novel, immunotherapy-based combination strategy that shrank a massive, chemo-resistant tumor burden and paved the way for a life-saving surgery.

Get Free Consultation Now

What is Dedifferentiated liposarcoma (DDLPS)?

Liposarcoma is a kind of malignant cancer that grows in the body’s fat tissues. Dedifferentiated liposarcoma is a specific, high-grade variant where a slow-growing fatty tumor transforms into a highly aggressive, fast-spreading cancer.

When DDLPS occurs directly within the peritoneal cavity, it does not just form a neat, isolated lump but instead, it spreads extensively across the abdominal surfaces, often wrapping completely around and encasing the bowel loops. It looks almost identical to other rare abdominal malignancies like mesothelioma or advanced peritoneal carcinomatosis on standard X-rays and scans. This makes pinpointing the exact disease is an immense medical hurdle. This makes finding a highly specific dedifferentiated liposarcoma treatment early on a major priority for survival.

The Patient Journey and Diagnostic Breakthrough by Dr. Manish Singhal

The case began when a 31-year-old male arrived at the clinic complaining of progressive, highly uncomfortable abdominal bloating and discomfort. Initial contrast-enhanced CT and MRI scans revealed extensive, worrying masses spreading heavily across the peritoneal surfaces. Advanced PET-CT imaging confirmed faintly FDG-avid soft tissue densities with internal hypodensity and clear encasement of the patient’s bowel loops.

The diagnostic road was filled with hurdles. An outside tissue biopsy initially misdiagnosed the patient’s condition as a malignant fibromyxoid sarcoma. Recognizing that the behavior of this intra-abdominal mass was highly unusual, Dr. Manish Singhal took charge and ordered an expert pathological review at Yashoda Medicity. This deep institutional review completely changed the playbook, revealing that the mass was actually a dedifferentiated liposarcoma (DDLPS) displaying unique epithelioid morphology.

Crucial Pathological and Immunohistochemical (IHC) Markers

To lock in the correct diagnosis, Dr. Manish Singhal and his laboratory team tracked highly specific cellular and molecular markers:

  • CDK4 Positive: Strong expression confirmed the true liposarcoma roots.
  • MDM2 Focal Expression: Further solidified the high-grade DDLPS profile.
  • Ki-67 Proliferative Index: Measured at approximately 15%, showing a steadily growing, aggressive malignancy.
  • S100 Protein: Negative, which successfully ruled out nerve-sheath tumors.
  • Cytokeratin (AE1/AE3): Showed focal positivity, aligning perfectly with the rare epithelioid shape of the cancer cells.

This case stands as proof of why an expert review by a specialist like Dr. Manish Singhal is so critical. A single diagnostic error can send a patient down an entirely wrong, ineffective path before they ever receive an accurate diagnosis and treatment for Dedifferentiated Liposarcoma.

Overcoming Traditional Treatment Roadblocks

Standard cancer therapies offer very bleak odds for patients dealing with advanced, refractory DDLPS. Conventional, aggressive chemotherapies generally produce weak and short-lived real-world responses. The patient’s early treatment timeline demonstrates just how aggressive this rare cancer can be:

  • Standard Chemotherapy: Four intensive cycles of anthracycline-based chemotherapy were administered which the patient has to initially undergo. Combining this with Ifosfamide and Adriamycin. Follow-up scans showed persistent disease with absolutely no significant tumor shrinkage or regression.
  • First-Line Targeted Therapy: Shifting strategies, the medical team administered an oral targeted drug called pazopanib. Unfortunately, imaging showed that the extensive peritoneal masses continued to hold their ground.

The Breakthrough: Dr. Manish Singhal’s Innovative Immunotherapy Approach

Faced with an aggressive cancer that refused to yield to standard chemotherapy and first-line targeted drugs, Dr. Manish Singhal designed an innovative, individualized dual-action regimen to serve as a specialized dedifferentiated liposarcoma treatment.

Dr. Manish Singhal initiated the use of the powerful immunotherapy drug Pembrolizumab, given at 100 mg intravenously every three weeks. This is paired with a targeted tyrosine kinase inhibitor (TKI). An interim PET-CT scan performed after just three cycles showed a highly favorable metabolic response. This proved that the immunotherapy was successfully training the patient’s immune cells to fight back.

To maximize this positive response and gain total control over the remaining disease, Dr. Manish Singhal enhanced the protocol by adding Cabozantinib, an oral targeted TKI taken daily at 40 mg. The addition of Cabozantinib completely turned the tide. A follow-up PET-CT scan revealed an outstanding clinical outcome: a marked, dramatic reduction in the overall tumor burden.

Turning a Dead End Into a Surgical Success

Dr. Manish Singhal achieved the ultimate goal of pre-operative therapy. By the use of immunotherapy to shrink the widespread, previously inoperable masses down to a manageable size. On May 12, 2026, the patient was successfully taken to the operating room for definitive cytoreductive surgery combined with Hyperthermic Intraperitoneal Chemotherapy.

This advanced, dual-action surgical approach allowed the team to physically remove all visible tumor masses. Helping in removing visible tumor masses before bathing the abdominal cavity directly with heated chemotherapy to destroy any remaining microscopic cancer cells on contact. This landmark protocol has opened a brand new door for effective dedifferentiated liposarcoma treatment planning.

Future Directions in Advanced Sarcoma Care

This remarkable case study from Yashoda Medicity offers vital new insights for the global oncology community. The work led by Dr. Manish Singhal highlights the massive potential. Potential in immunotherapy-based drug combinations to treat refractory, chemo-resistant, dedifferentiated liposarcoma (DDLPS). It also underscores how specific molecular vulnerabilities like CDK4 and MDM2 positivity can be exploited to design highly sensitive, successful targeted regimens.

While further clinical research and larger trials are still required to establish the absolutely perfect way to integrate immunotherapy into advanced liposarcoma care, this clinical finding provides an immediate ray of hope. It proves that even when rare cancers present in highly atypical ways, partnering with an expert team led by Dr. Manish Singhal can rewrite a patient’s prognosis, providing a reliable dedifferentiated liposarcoma treatment and delivering a second chance at a healthy life.